Study in "Translational Psychiatry" explores plasma proteins related to the p-factor in young adults, revealing potential biomarkers for overall mental health status and insights into common ...

A recent study from Harvard Medical School asks whether the element lithium might be a key factor in whether someone develops Alzheimer’s disease.

Plasma p-tau217 detected plaques and tangles in cognitively normal and impaired adults. The marker also pegged people with rapid memory decline. Screening with p-tau217 may halve the number of trial ...

New research published in the July issue of the Journal of the American College of Surgeons shows elevated plasma DNA is a reliable marker of recurrent esophageal cancer. The study also suggests ...

The results suggest that plasma PTX3 levels may not only be laboratory values that differentiate NASH from non-NASH, but marker of the severity of hepatic fibrosis in NASH.

Conclusions: Changes in plasma heparanase levels correlated with response to treatment for all of the children diagnosed with cancer. This provides a rationale for exploring clinical interest in ...

Plasma ctDNA response is an early phenomenon, with the majority of change detectable within the first cycle of therapy. These kinetics may offer an opportunity for early insight into treatment effect ...

If true, this nuanced view would peg plasma Aβ42/40 ratio as the very first marker to change in AD. This could have implications for the basic understanding of Alzheimer’s pathophysiology and ...

CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good tolerability.

Plasma PTX3 measurements may be noninvasive and appear to show promise as a means to differentiate NASH from non-NASH patients, and as a clinical marker of the severity of liver fibrosis in NASH ...